Biotechnology movers and shakers on the move. Read new hires, promotions of executives, and more.
“It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “The combination of their regulatory, commercial and marketing expertise is invaluable as we advance our RPT193 program into late stage trials in atopic dermatitis and asthma and continue development of FLX475 program in multiple cancer indications.”
Christoper Prentiss joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials at the end of the year. ADARx has two additional drug candidates set to enter clinical trials next year and an extensive pipeline to follow.
Epiphany Technology Acquisition Corp. notes the Board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of the Company.
In addition to serving as interim CEO, Ms. Curley will remain CFO. The iSpecimen Board of Directors (the “Board”) is currently reviewing the Company’s near- and long-term needs pertaining to the role of Chief Executive Officer.
Alliance Pharma notes their new leaders will support continued global expansion, which includes the company's recent acquisition of U.K.-based Drug Development Solutions from LGC and new bioanalytical laboratory opening in Australia in November.
Dr Catherine Mohr has a great deal of experience that spans several areas, including surgery, medical technology, engineering, product development and design, healthcare, alternative energy, automotive, aerospace, global entrepreneurship, Intellectual Property Litigation, U.S Food & Drug Administration compliance, and education.